BioCryst to present new ORLADEYO clinical data at ACAAI meeting
BCRX•BioCryst will present four hereditary angioedema abstracts at the ACAAI annual scientific meeting in Phoenix from Nov. 12-16, 2026, including data on ORLADEYO and interim results for investigational navenibart.
1. Meeting presentations
BioCryst will present four abstracts on hereditary angioedema. ORLADEYO presentations will cover reduced hospitalizations, emergency department visits and healthcare use among patients starting or switching preventive treatment, while pediatric research will examine growth-related dose adjustments.
2. Navenibart research
Interim results from the ALPHA-SOLAR study of investigational injectable navenibart will address long-term safety, efficacy and quality of life in hereditary angioedema.
